바이오칩 시장 보고서 : 제품 유형별, 제조 기술별, 분석 방법별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global biochips market size reached USD 25.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 77.6 Billion by 2034, exhibiting a growth rate (CAGR) of 12.88% during 2026-2034. North America dominates the market because of its robust healthcare system, considerable investments in research operations, and sophisticated medical technologies. The market is experiencing steady growth driven by innovations in next-generation sequencing and lab-on-a-chip technologies to enhance biochip capabilities, substantial funding from governments and private sectors for genetic and molecular research, and the increasing demand for personalized medicine.

As personalized medicine becomes more prevalent, biochips are essential in customizing treatments based on the genetic profile of an individual. These chips assist in identifying genetic mutations, early disease detection, and predicting drug responses, thereby catalyzing the demand for biochips in healthcare and pharmaceutical sectors. In addition, biochips are increasingly being utilized in point-of-care (POC) diagnostics, where immediate results are crucial for decision-making. Their ability to deliver quick, accurate results at the patient's location, whether at a clinic, in the field, or at home, is revolutionizing healthcare delivery. Apart from this, advancements in genomics, proteomics, and molecular biology are making biochips vital instruments for the analysis of biological samples. This enables quicker, more accurate research and diagnostics, rendering them essential in laboratories, hospitals, and clinical environments.

Biochips Market Trends:

Rising Demand for Personalized Medicine

Healthcare providers are progressively embracing a more personalized strategy to treatment, concentrating on the distinct genetic composition and biomarker characteristics of every patient. Biochips are ideal for performing the essential genetic evaluations needed to establish individualized treatment strategies. Their capacity to quickly identify particular genetic mutations, variations, and gene expressions allows healthcare providers to customize treatments for the best patient results. With the rise of precision medicine, there is an increase in the need for biochips capable of conducting comprehensive, high-throughput screening and diagnostic evaluations. These sophisticated biochips can manage intricate biological information and support more precise therapies, allowing doctors to offer improved care for their patients. As a result, biochips are becoming essential instruments in the continuous progress of personalized medicine.

Advancements in 3D Printing and Microfluidic Biochips

Progress in 3D printing and microfluidic biochips is considerably supporting the expansion of the biochips market. The capability to accurately replicate human organ functions is transforming research in life sciences and pharmaceutical testing. In May 2024, Boston Micro Fabrication (BMF) established BMF Biotechnology Inc., a division dedicated to 3D-printed organ-on-a-chip BioChips. These microfluidic systems provided improved biological precision over conventional models, facilitating quicker and more accurate research results. This advancement enhanced drug testing, cosmetic safety, and treatment forecasting by delivering more accurate simulations of human organs. Such innovations are expanding the limits of biological research and opening up new possibilities for biochip uses, especially in personalized medicine and drug development. The ongoing advancement of 3D-printed biochips improves their effectiveness, increasing the need for innovative biochip technologies in multiple research and healthcare fields.

Government Support and Investments in Biotechnology

Support from the government and targeted investments in biotechnology are crucial factors propelling the growth of the biochips market. Through the funding of pioneering projects, governments are facilitating the advancement of cutting-edge biochip technologies applicable to multiple fields, such as healthcare, research, and high-tech sectors. A notable instance of this is the US$31 million funding by the Israel Innovation Authority in 2024 to establish the nation's inaugural biochip lab. Created in partnership with Israel Aerospace Industries and Beckermus Technologies, this laboratory aimed to promote biotechnology and strengthen Israel's position in the global market. With US$20.56 million in funding provided by the Authority, this initiative underscored the growing acknowledgment of biochips as essential elements for advancements in science and medicine. Government initiatives aimed at developing biochip infrastructure play a crucial role in market growth, enhancing technological advancements and easing the integration of biochips in industries worldwide.

Biochips Market Growth Drivers:

Growing Geriatric Population

With the global rise in life expectancy, there is a higher need for healthcare solutions that can meet the unique requirements of an older demographic. This demographic shift presents novel challenges, particularly in disease identification, tracking, and management. The World Health Organization (WHO) states that by 2030, one in six individuals globally will be 60 years or older, and by 2050, the worldwide population of people aged 60 and over is anticipated to increase to 2.1 billion. This changing demographic is catalyzing the demand for efficient diagnostic tools capable of identifying illnesses at early stages and tracking chronic conditions, like cancer, cardiovascular diseases, and diabetes, which are more common among older individuals. Biochips, recognized for their swift and precise outcomes, are becoming an optimal answer to satisfy these needs, fueling the growth of the biochips market within healthcare industries.

Technological Advancements and Innovation

The ongoing advancement of advanced and efficient biochips is greatly improving the functionalities of biochips, allowing for better processing power, enhanced throughput, and higher accuracy in detecting biological markers. Advancements in microarray technology, miniaturization, and sensor integration enable biochips to conduct intricate analyses more quickly and reliably. These innovations are broadening the uses of biochips, particularly in diagnostics, personalized medicine, and drug discovery, where accuracy and speed are essential. Moreover, the incorporation of AI and ML with biochip technology is transforming data analysis, allowing for enhanced predictions and better clinical decision-making. This combination of technologies improves the overall efficacy of biochips and encourages their use in healthcare and research domains. The growing need for improved diagnostics and precise therapies is catalyzing the demand for biochips fot providing cutting-edge options for various medical and research purposes.

Expansion of Healthcare Access

The increasing emphasis on enhancing healthcare access is a crucial factor contributing to the market growth. As healthcare systems develop, the demand for affordable and efficient diagnostic tools grows. Biochips provide an effective answer, particularly in distant or underserved regions where sophisticated lab facilities might be limited. Their small dimensions, simplicity of operation, and capability to deliver quick outcomes render biochips perfect for point-of-care environments. For example, in 2025, Mount Sinai Medical Center expanded primary care services to underserved communities in South Florida with the opening of its new Hialeah East outpatient facility. This expansion supports their mission to improve healthcare access and equity. Such efforts benefits from the deployment of biochips for quick, accessible diagnostics. As investments in healthcare infrastructure grow, biochips are increasingly being integrated into global healthcare systems.

Biochips Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the global biochips market report, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on product type, fabrication technique, analysis method, application, and end user.

Breakup by Product Type:

• DNA Chip
• Protein Chip
• Lab-On-a-Chip
• Enzyme Chip

DNA Chip represents the largest market segment

DNA chips, otherwise called DNA microarrays, are currently the largest product type in the market. This can be supported by the wide application spectrum and technological advances. These chips facilitate large-scale analyses of genetic information; such chips become core tools in genomics, diagnostics, and personalized medicine. Thousands of genes can be analyzed simultaneously, hence making landmark changes in research related to cancer genomics, genetic disorder screening, and pharmacogenomics. It is resulting in more sensitive, specific, and efficient DNA chips with upgraded technologies, thereby increasing adoption. According to the biochips market report, the growing interest in precision medicine and health treatments by individual genomics also accelerates the demand for DNA chips. Key players in the marketplace are engaged in extensive research and development to come up with new products in DNA chips, thereby helping the changing requirements of healthcare and biotech companies. Apart from this, increasing incidences of genetic disorders and chronic diseases require detailed genetic profiling, and thus, DNA chips assume a significant role in contemporary diagnostics and therapy. DNA chips, therefore, hold a greater share in the biochips market since they represent a vital constituent in promoting molecular biology and individualistic healthcare solutions.

Breakup by Fabrication Technique:

• Microarray
• Microfluidic

Microarray represents the largest market segment

Microarray technology is the most widely used fabrication technique in this market due to its versatility and efficiency for different applications. This method permits large amounts of biological data to be analyzed at the same time and is used in genomics, transcriptomics, and proteomic studies. The biochips market forecast suggests that quantification of gene or protein expression across the spectrum in a single experiment is game-changing for drug discovery, disease diagnosis, and personalized medicine. New microarray technologies support more accurate, faster, and scaled-up biochip fabrication to enable reliable detection over large fractions of the corresponding user population. Microarray technology is widely used in the healthcare and bioinformatics sectors to improve research activities, as well as help introduce new targeted therapies. Additionally, their integration with modern data analysis techniques and bioinformatics platforms is further expanding the use of microarrays for understanding complex biological processes. With the growth of personalized medicine, the coming years will see a great increase in demand for accurate and high-throughput analytical platforms such as microarrays. Hence, microarray technology continues to be the leading method of manufacturing in the marketplace and plays a foundational role in propelling biomedical research forward as well as improving clinical diagnostics.

Breakup by Analysis Method:

• Electrophoresis
• Luminescence
• Mass Spectrometry
• Electrical Signals
• Magnetism

Electrophoresis represents the largest market segment

Electrophoresis is the most dominant method of analysis in biochips due to its wide applicability, strength, and precision in separation techniques, and the analysis of biological molecules. This also represents a vital technique in functional genomics, proteomics, and molecular biology through the effective separation of DNA, RNA, and proteins, based on size and charge, offering a view into their structure and function. According to the biochips market overview, electrophoresis is being utilized in several research and routine laboratories, especially in tasks related to genetic mapping, disease diagnosis, and forensic analysis. This, in addition to being a robust and accurate system, permitted working in unison with advanced biochip technologies to ensure better resolution and higher throughput of molecular analyses. Electrophoresis techniques, including capillary and microfluidic electrophoresis, have recently been innovated to further enhance its operations, moving faster and offering more detailed examinations. Evident through the increasing need for high-precision analytical tools within the fields of personalized medicine and biotechnology, electrophoresis is set to remain prominent. Moreover, it consolidates a central position as the leading analysis method in the market with the escalating complex biological systems and disease mechanisms.

Breakup by Application:

• Molecular Analysis
• Hybridization
• Protein
• Immunological
• Biomolecules
• Biomarker
• Others
• Diagnosis
• Gene Diagnosis
• Oncology
• Inflammatory
• Others
• Non-Biological Usage

Diagnosis represents the largest market segment

Diagnosis is the largest application in the market as an accurate, fast, and comprehensive diagnostic tool is necessary in healthcare. Biochips are revolutionizing the concept of diagnosis in that they can analyze multiple biomarkers in a single chip, helping in the early and accurate detection of diseases. Therefore, this is escalating the biochips demand. This is important in managing chronic and infectious diseases, such as cancer, cardiovascular disorders, and emerging viral infections. These factors are leading to the integration of biochips in diagnostic platforms, which further resulted in enhanced specificity and sensitivity of tests, thereby leading toward better patient outcomes, based on test results, through timely and targeted interventions. Apart from this, progress in biochip technology in the form of microarrays and lab-on-a-chip systems has made things easier, cost-effective, and more accessible at the diagnostic level. The stakes for diagnostics based on biochips are further raised by the rise of personalized medicine, as these will be able to render analyses of genetic profiles to administer treatments on an individual basis. With the changing landscape of healthcare across the globe toward precision and preventive medicine, the adoption of biochips for diagnostic purposes is gaining considerable ground, which essentially sets this as a cornerstone in modern medical diagnostics and fuels the biochips market growth.

Breakup by End User:

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostics Centers
• Academic and Research Institutes
• Others

Pharmaceutical and biotechnology companies represent the largest market segment

The largest end users in the biochips industry are pharmaceuticals and biotechnology firms. This can be attributed to their extensive research and development activities and increased demand for new and fresh solutions in drug discovery and development processes. Biochips help these sectors immensely in areas such as high-throughput screening, gene analysis, and biomarker identification for the comprehension of the mechanisms of diseases and the subsequent development of targeted therapies. Additionally, biochip technology makes possible new technologically precise, faster, and less expensive methods that hasten drug development and inform and facilitate the planning of clinical trials, hence putting personalized medicine into action with detailed molecular insight. In regard to this, the heavy investments in biochip technology by the studied firms is to improve efficiency and lower development costs. Moreover, close collaboration between the manufacturers of biochips and pharmaceutical and biotech companies fosters further improved forms of biochips tailored to special research needs. With continued pressure from the rising need for new therapeutics and personalized treatment options, there is a growing reliance on biochips within these industries, and it can create a critical difference in innovating and building a competitive edge to deal with the transforming environment of healthcare.

Breakup by Region:

• North America
• United States
• Canada
• Europe
• Germany
• France
• United Kingdom
• Spain
• Russia
• Italy
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Others
• Latin America
• Mexico
• Brazil
• Argentina
• Others
• Middle East and Africa
• Turkey
• Saudi Arabia
• United Arab Emirates
• Others

North America leads the market, accounting for the largest biochips market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Spain, Russia, Italy, and others); Asia Pacific (China, India, Japan, South Korea, Australia, and others); Latin America (Mexico, Brazil, Argentina, and others); and the Middle East and Africa (Turkey, Saudi Arabia, United Arab Emirates, and others). According to the report, North America represents the largest regional market for biochips.

The North America region is the largest contributor to the biochips market due to high-quality healthcare infrastructure and substantial investments in biotechnology research, followed by Asia-Pacific being robustly driven by technological innovation. Besides, the sovereignty of this region is also driven by some major market players in biotech, such as Samsung Biologics and Celltrion, along with comprehensive government support for R&D activities. Along with this, rising chronic diseases and personalized medicine requirements are further fueling a rise in the usage of biochip technologies. Prospective growth opportunities for this market in major countries such as the U.S. and Canada are propelling regional expansion due to genomics and proteomics research grants which are augmenting the biochips market revenue. In addition, the presence of mature pharmaceutical and biotechnology industries in North America allows expeditious commercialization and adoption of biochip applications across diverse healthcare settings.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the biochips industry include:

• Agilent Technologies, Inc.
• bioMerieux SA
• Bio-RAD Laboratories, Inc.
• CapitalBio Corporation
• Dynamic Biosensors GmbH
• EMD Millipore Corporation
• Fluidigm Corporation
• Illumina, Inc.
• Perkinelmer, Inc.
• Thermo Fisher Scientific Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The leading biochips companies are engaged in research and development with respect to new products and technological innovations to enhance the existing technology. Major companies such as Illumina, Thermo Fisher Scientific, and Agilent Technologies execute next-generation sequencing and lab-on-chip systems. This develops sensitivity, accuracy, and throughput, hence meeting demand for precise diagnostic and research tools. Such strategic collaborations, mergers, and acquisitions often allow these firms to develop their product line and increase their geographical presence. They are also integrating the biochip technology with artificial intelligence and machine learning, which enhances the data analysis capability. These major players, therefore, meet changing requirements in personalized medicine, diagnostics, and drug discovery, hence maintaining a competitive edge and accelerating the market growth.

Key Questions Answered in This Report:

• How has the global biochips market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global biochips market?
• What is the impact of each driver, restraint, and opportunity on the global biochips market?
• What are the key regional markets?
• Which countries represent the most attractive biochips market?
• What is the breakup of the market based on the product type?
• Which is the most attractive product type in the biochips market?
• What is the breakup of the market based on the fabrication technique?
• Which is the most attractive fabrication technique in the biochips market?
• What is the breakup of the market based on the analysis method?
• Which is the most attractive analysis method in the biochips market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the biochips market?
• What is the breakup of the market based on the end user?
• Which is the most attractive end user in the biochips market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global biochips market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Biochips Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 DNA Chip
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Protein Chip
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Lab-On-a-Chip
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Enzyme Chip
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Fabrication Technique

• 7.1 Microarray
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Microfluidic
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Analysis Method

• 8.1 Electrophoresis
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Luminescence
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Mass Spectrometry
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Electrical Signals
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Magnetism
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Application

• 9.1 Molecular Analysis
  • 9.1.1 Hybridization
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Protein
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
  • 9.1.3 Immunological
    • 9.1.3.1 Market Trends
    • 9.1.3.2 Market Forecast
  • 9.1.4 Biomolecules
    • 9.1.4.1 Market Trends
    • 9.1.4.2 Market Forecast
  • 9.1.5 Biomarker
    • 9.1.5.1 Market Trends
    • 9.1.5.2 Market Forecast
  • 9.1.6 Others
    • 9.1.6.1 Market Trends
    • 9.1.6.2 Market Forecast
• 9.2 Diagnosis
  • 9.2.1 Gene Diagnosis
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Oncology
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 Inflammatory
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 Others
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
• 9.3 Non-Biological Usage
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by End User

• 10.1 Pharmaceutical and Biotechnology Companies
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Hospitals and Diagnostics Centers
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Academic & Research Institutes
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Europe
  • 11.2.1 Germany
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 France
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 United Kingdom
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 Spain
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Russia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Italy
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Asia Pacific
  • 11.3.1 China
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 India
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 Japan
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 South Korea
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Australia
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Others
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Mexico
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Brazil
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Argentina
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
  • 11.4.4 Others
    • 11.4.4.1 Market Trends
    • 11.4.4.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Turkey
    • 11.5.1.1 Market Trends
    • 11.5.1.2 Market Forecast
  • 11.5.2 Saudi Arabia
    • 11.5.2.1 Market Trends
    • 11.5.2.2 Market Forecast
  • 11.5.3 United Arab Emirates
    • 11.5.3.1 Market Trends
    • 11.5.3.2 Market Forecast
  • 11.5.4 Others
    • 11.5.4.1 Market Trends
    • 11.5.4.2 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Agilent Technologies, Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 bioMerieux SA
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bio-RAD Laboratories, Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 CapitalBio Corporation
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Dynamic Biosensors GmbH
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 EMD Millipore Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Fluidigm Corporation
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
  • 15.3.8 Illumina, Inc.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Perkinelmer, Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Thermo Fisher Scientific, Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis